Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

Abstract Background Amrubicin chemotherapy is a treatment option for patients with non‐small cell lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo‐II), a target of amrubicin, has been reported to be a prognostic or predictive marker for chemosensitivity and cl...

Full description

Bibliographic Details
Main Authors: Reiko Sakurai, Kyoichi Kaira, Yosuke Miura, Noriaki Sunaga, Ryusei Saito, Tetsunari Oyama, Takeshi Hisada, Masanobu Yamada
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Thoracic Cancer
Subjects:
Amrubicin
non‐small cell lung cancer
prognostication
topoisomerase‐II
Online Access:https://doi.org/10.1111/1759-7714.13289

Internet

https://doi.org/10.1111/1759-7714.13289

Similar Items